Skip to main content
Gabriel Vargas, MD, Psychiatry, San Francisco, CA

GabrielA.VargasMDPhD

Psychiatry • San Francisco, CA

Physician

Join to view full profile

Dr. Vargas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Vargas' full profile

Already have an account?

  • Office

    401 Parnassus Ave
    San Francisco, CA 94143
    Phone+1 415-476-7500
    Fax+1 415-502-6361

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Residency, Psychiatry, 1997 - 2001
  • University of California, Irvine, School of Medicine
    University of California, Irvine, School of MedicineClass of 1997

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1998 - 2026

Publications & Presentations

PubMed

Press Mentions

  • CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease
    CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s DiseaseNovember 9th, 2021
  • CuraSen Therapeutics Announces Phase 1 Clinical Data Demonstrating That Salbutamol, a Beta-2 Adrenoceptor Agonist, Significantly Increases Cerebral Perfusion, a Key Marker in Neurodegenerative Disease
    CuraSen Therapeutics Announces Phase 1 Clinical Data Demonstrating That Salbutamol, a Beta-2 Adrenoceptor Agonist, Significantly Increases Cerebral Perfusion, a Key Marker in Neurodegenerative DiseaseMarch 15th, 2021
  • CuraSen Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial with First Proprietary Compound, CST-2032, Targeting Neurodegenerative Disease
    CuraSen Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial with First Proprietary Compound, CST-2032, Targeting Neurodegenerative DiseaseSeptember 15th, 2020

Grant Support

  • Membrane Trafficking Regulation Of Dopamine ReceptorsNational Institute Of Mental Health2003–2006

Other Languages

  • Spanish

Dr. Gabriel Vargas, Dr. Gabriel Vargas, MD, Dr. G Vargas, Dr. Gabriel A. Vargas